MINNEAPOLIS, Sept. 4, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that its Urgent® PC Neuromodulation System will be included as part of a neuromodulation workshop at the Annual Meeting of the International Urogynecological Association (IUGA) in Brisbane, Australia to be held September 4-8, 2012.
"The neuromodulation workshop faculty consists of world renowned urologists and urogynecologists who will be presenting on several forms of neuromodulation used to treat voiding dysfunction. We are pleased to have Urgent PC included as one of these clinically effective therapies," said David Kaysen, President and CEO of Uroplasty. "This is consistent with the recent AUA/SUFU guidelines on OAB diagnosis and therapy that also include Urgent PC."
"Dr. Stefano Salvatore, Professor of Urogynecology, University of Insubria, Varese, Italy will present the clinical data that demonstrate Urgent PC's clinically significant improvements, as well as his own extensive experience with UPC within his practice. We are pleased with the growing awareness of Urgent PC as a safe, effective means to address the symptoms of overactive gladder. Urgent PC is taking its rightful place on the international stage with other neuromodulation therapies," concluded Mr. Kaysen.
The International Urogynecological Association (IUGA) is a non-profit international organization dedicated to the advancement of urogynecological knowledge around the world through education and the promotion of basic and clinical research on disorders of the female pelvic floor. IUGA was founded in 1975 and has organized scientific meetings every year in nearly every corner of the world to promote the exchange of urogynecological information to thousands of physicians and healthcare providers. At the 2012 meeting, over 2,000 urogynecologists, nurses and physical therapists attendees are expected.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
David Kaysen, President and CEO, or
Medi Jiwani, Vice President, CFO, and Treasurer,
Jenifer Kirtland (Investors)
Chris Gale (Media)
SOURCE Uroplasty, Inc.